D.E. Shaw & Co’s Alnylam Pharmaceuticals ALNY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$106M Sell
429,100
-1,200
-0.3% -$305K 0.05% 430
2026
Q2
$130M Buy
430,300
+21,500
+5% +$6.48M 0.06% 354
2026
Q1
$135M Buy
408,800
+11,600
+3% +$3.95M 0.08% 284
2025
Q4
$158M Buy
397,200
+365,300
+1,145% +$162M 0.09% 263
2025
Q3
$14.5M Buy
31,900
+30,300
+1,894% +$12.3M 0.01% 1402
2025
Q2
$522K Hold
1,600
– – ﹤0.01% 3627
2025
Q1
$432K Sell
1,600
-22,000
-93% -$5.65M ﹤0.01% 3577
2024
Q4
$5.55M Hold
23,600
– – ﹤0.01% 1887
2024
Q3
$6.49M Hold
23,600
– – 0.01% 1749
2024
Q2
$5.73M Sell
23,600
-82,700
-78% -$13.1M 0.01% 1743
2024
Q1
$15.9M Buy
106,300
+39,300
+59% +$6.56M 0.01% 1066
2023
Q4
$12.8M Buy
67,000
+10,400
+18% +$1.77M 0.01% 1198
2023
Q3
$10M Buy
56,600
+13,200
+30% +$2.52M 0.01% 1283
2023
Q2
$8.24M Hold
43,400
– – 0.01% 1496
2023
Q1
$8.69M Sell
43,400
-10,000
-19% -$2.1M 0.01% 1481
2022
Q4
$12.7M Buy
53,400
+13,400
+34% +$2.86M 0.01% 1238
2022
Q3
$8.01M Hold
40,000
– – 0.01% 1562
2022
Q2
$5.83M Buy
40,000
+10,000
+33% +$1.42M 0.01% 1940
2022
Q1
$4.9M Hold
30,000
– – ﹤0.01% 2337
2021
Q4
$5.09M Buy
+30,000
New +$5.58M ﹤0.01% 2356
2021
Q3
– Sell
-21,000
Closed -$3.56M – 4933
2021
Q2
$3.56M Sell
21,000
-9,000
-30% -$1.32M ﹤0.01% 2345
2021
Q1
$4.24M Sell
30,000
-22,800
-43% -$3.43M ﹤0.01% 1976
2020
Q4
$6.86M Hold
52,800
– – 0.01% 1627
2020
Q3
$7.69M Sell
52,800
-20,000
-27% -$2.84M 0.01% 1409
2020
Q2
$10.8M Buy
72,800
+17,300
+31% +$2.33M 0.01% 1153
2020
Q1
$6.04M Buy
55,500
+5,000
+10% +$577K 0.01% 1326
2019
Q4
$5.82M Buy
50,500
+15,500
+44% +$1.55M 0.01% 1609
2019
Q3
$2.82M Hold
35,000
– – ﹤0.01% 2101
2019
Q2
$2.54M Sell
35,000
-20,000
-36% -$1.53M ﹤0.01% 2068
2019
Q1
$5.14M Buy
55,000
+4,000
+8% +$335K 0.01% 1535
2018
Q4
$3.72M Buy
51,000
+600
+1% +$46.2K 0.01% 1710
2018
Q3
$4.41M Buy
50,400
+35,400
+236% +$3.56M 0.01% 1655
2018
Q2
$1.48M Hold
15,000
– – ﹤0.01% 2438
2018
Q1
$1.79M Buy
15,000
+5,000
+50% +$645K ﹤0.01% 2122
2017
Q4
$1.27M Hold
10,000
– – ﹤0.01% 2442
2017
Q3
$1.18M Hold
10,000
– – ﹤0.01% 2398
2017
Q2
$798K Buy
+10,000
New +$639K ﹤0.01% 2548
2015
Q2
– Sell
-10,000
Closed -$1.04M – 3726
2015
Q1
$1.04M Buy
+10,000
New +$1.01M ﹤0.01% 2530
2014
Q2
– Sell
-8,800
Closed -$591K – 4146
2014
Q1
$591K Hold
8,800
– – ﹤0.01% 3455
2013
Q4
$566K Buy
+8,800
New +$525K ﹤0.01% 3640

Other funds holding ALNY

D.E. Shaw & Co's ALNY Position: Q3 2026 in Review

D.E. Shaw & Co reduced its Alnylam Pharmaceuticals (ALNY) stake by 2% in Q3 2026, selling an estimated $5.49M and leaving 1,082,529 shares worth $267M. The position accounts for 0.13% of the portfolio, ranked #163.

D.E. Shaw & Co first reported a position in ALNY in Q2 2013 and has held it in 54 quarters since. The position peaked at $350M in Q1 2026. 730 funds tracked by Wall St. Rank hold ALNY as of Q3 2026.

  • D.E. Shaw & Co held 1,082,529 shares of Alnylam Pharmaceuticals worth $267M as of Q3 2026.
  • D.E. Shaw & Co sold 21,580 Alnylam Pharmaceuticals shares in Q3 2026, an estimated $5.49M.
  • Alnylam Pharmaceuticals made up 0.13% of D.E. Shaw & Co's portfolio in Q3 2026, its #163 holding.
  • D.E. Shaw & Co first reported a position in Alnylam Pharmaceuticals in Q2 2013 and has held it in 54 quarters since.
  • D.E. Shaw & Co's Alnylam Pharmaceuticals position peaked at $350M in Q1 2026.
  • 730 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2026.

Based on D.E. Shaw & Co's 13F filing for Q3 2026, filed 16 Nov 2026.